SINTX发布重要第三季度业务更新与财务亮点,受到FDA批准、产品和知识产权组合扩展以及运营效率提升的推动。
SINTX发布重要第三季度业务更新与财务亮点,受到FDA批准、产品和知识产权组合扩展以及运营效率提升的推动。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.